Axoft Secures $55M Series A to Advance Global Clinical Trials for Bio-Inspired Brain-Computer Interface
Axoft, a neurotechnology company, has successfully raised $55 million in an oversubscribed Series A funding round, intended to support the expansion of its clinical trials globally and to progress U.S. regulatory approval for its implantable Brain-Computer Interface.
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Axoft, a neurotechnology company, today announced it has raised an oversubscribed $55 million Series A led by C.P. Group Innovation. Alumni Ventures, the Stanford President’s Venture Fund, Hillhouse Investment and Gaorong Ventures also participated in the round. With more than $60 million in total funding raised, Axoft will use the capital to expand its current clinical trials globally and progress U.S. regulatory approval of its implantable Brain-Computer Int